| 摘要 |
The present invention concerns a compound for use in a method of treating a neoplasm associated with overexpression or amplification of HER-2 in a subject, wherein i) the compound is selected from HKI-272, or a pharmaceutically acceptable salt thereof; ii) the method further comprises administering: 1) a second compound selected from vinorelbine, or a pharmaceutically acceptable salt thereof; and 2) a taxane selected from docetaxel or paclitaxel. According to further embodiments, the invention concerns a unit dose for such use, comprising HKI-272, or a pharmaceutically acceptable salt thereof and also concerns a product for such use, comprising HKI-272, or a pharmaceutically acceptable salt thereof, vinorelbine or a pharmaceutically acceptable salt thereof and a taxane. |
